Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
← catalyst calendarSponsored by Can-Fite BioPharma (industry) · CANF — their whole pipeline →.
Phase
Phase 2
Status
Unknown status
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
114estimated
Sites
24
Countries
Bosnia and Herzegovina, Bulgaria, Israel +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-10 | actual | When the study began enrolling |
| Primary completion | 2025-04-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2021-01-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NASH - Nonalcoholic Steatohepatitis
Interventions
- Drug: Namodenoson — also filed as CF102
- Drug: Placebo — also filed as Inactive control
Primary outcomes
what the primary-completion date above is the date OFNon-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS)
measured 36 weeks
Adverse events (AEs)
measured 36 weeks
Publications
- PMID 21660967 — cited as background
- PMID 34671996 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CANF's whole pipeline · Catalyst calendar · Every registered study · What changed